Integrating interacting drugs and genetic variations to improve the predictability of warfarin maintenance dose in Chinese patients.

Pharmacogenetics and genomics

Volumn 22, Issue 3, 2012, Pages 176-182

  Zhong, Shi Long ^a   Yu, Xi Yong ^b   Liu, Yuan ^b   Xu, Dan ^b   Mai, Li Ping ^b   Tan, Hong Hong ^b   Lin, Qiu Xiong ^b   Yang, Min ^b   Lin, Shu Guang ^b  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CYP2C9 PROTEIN, HUMAN; CYP4F2 PROTEIN, HUMAN; CYTOCHROME P450; MENADIONE EPOXIDASE; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE; WARFARIN;

ADULT; ARTICLE; CHINA; DOSE RESPONSE; DRUG INTERACTION; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENETICS; GENOTYPE; HEART VALVE REPLACEMENT; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; POSTOPERATIVE PERIOD;

ADULT; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; CHINA; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC VARIATION; GENOTYPE; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POSTOPERATIVE PERIOD; WARFARIN;

EID: 85027928243     PISSN: None     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/fpc.0b013e32834f45f9     Document Type: Article

References (0)